China's Dizal Pharma has entered into an exclusive global licence agreement with AstraZeneca (AZ) for Zegfrovy (sunvozertinib), an oral, irreversible, highly selective EGFR tyrosine kinase inhibitor (TKI) approved in China and the US for previously treated EGFR exon 20 insertion non-small cell lung cancer (NSCLC). AZ will pay USD 600 million upfront, up to USD 400 million in clinical development milestones, up to USD 500 million in commercial milestones, and tiered royalties ranging from high single digits to low double digits on global net sales.

Sunvozertinib is under review for a first-line NSCLC indication in both China and the US based on positive Phase III WU-KONG28 data, having received Breakthrough Therapy Designations (BTD) from both countries' regulators.